Navigation Links
Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices

PHILADELPHIA, Jan. 15 /PRNewswire/ -- Eli Lilly and Company announced today it has agreed to plead guilty to criminal conduct and to pay more than 1.4 billion in criminal and civil fines, penalties and damages arising from allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for its blockbuster atypical antipsychotic, Zyprexa. The settlement is the largest qui tam settlement in U.S. history.

Lilly engaged in a nationwide campaign to market Zyprexa off-label for untested and unapproved uses and, as part of that campaign, Lilly minimized and misrepresented the dangers of Zyprexa, placing company profits above the public safety according to two qui tam Complaints filed by whistleblower attorneys Brian Kenney and Tavy Deming of Kenney, Egan, McCafferty & Young ("KEMY").

The qui tam Complaints were filed on behalf of Steven Woodward, a former Lilly Long Term Care ("LTC") Zyprexa sales representatives from Florida and Jaydeen Vicente a former Lilly LTC representative from California. The Complaints were the first qui tam claims to focus on off-label marketing in Lilly's Long Term Care Sales division.

The Complaints allege that Lilly established a LTC sales force created for a singular purpose - to promote Zyprexa exclusively off-label by extolling the drug's efficacy for a litany of non-indicated uses to control through sedation elderly nursing home residents exhibiting symptoms of agitation, anxiety, insomnia. Lilly staffed the LTC sales force with 180 "specialty" sales representatives, chosen for their special skill sets that translated into heightened aptitude for selling. Lilly's aggressive LTC sales approach succeeded. According to the Woodward and Vicente complaints, the off-label Zyprexa revenues generated per LTC sales representative far exceeded the revenues generated per representative in any other Zyprexa sales division.

According to Deming, Lilly had no legitimate purpose in creating a sales force to call upon nursing homes and other elder care facilities because Zyprexa is not approved for any use in that patient population in addition to the fact that the typical residents of these homes were not schizophrenic or bipolar. "Our clients questioned their superiors about the legality of Lilly's Zyprexa marketing practices," explained Deming, "but they were instructed that as long as they adhered to Lilly's LTC marketing message, the LTC marketing tactics were not illegal."

Because of the lack of any FDA-approved use in the LTC demographic, LTC sales representatives were instructed to focus on "behavior treatment," i.e., Zyprexa's efficacy in treating disruptive and combative patients and patients exhibiting signs of anxiety, depression, and loss of concentration who were demanding of caregiver time and effort. Lilly's Zyprexa marketing arm, the Zyprexa Brand Team, created marketing tools tailored to the LTC symptom-based sales message, such as colorful visual detail aids that stressed Zyprexa's ability to "restore calm" in elderly patients.

Because one of Zyprexa's primary side effects is somnolence or drowsiness, Zyprexa was often used to sedate patients, a practice that was commonly referred to as "snowing." According to Kenney, "Lilly even devised a LTC sales slogan used nationwide - '5 at 5 pm,' which was shorthand for dosing elderly patients with 5 milligrams of Zyprexa at 5 pm to keep patients calm throughout the night." "It's particularly disturbing that such a potent drug, with so many serious adverse side effects, was so blatantly abused in a vulnerable patient population whose health is already at risk," stated Kenney. Kenney added that "at many nursing homes this potent antipsychotic was essentially used as a 'chemical restraint' for the elderly for whom Zyprexa had no other health benefit."

The Zyprexa's label currently bears a black box warning, the FDA's strongest warning, cautioning of the increased risk of death when Zyprexa is used to treat elderly patients with dementia. According to Deming, "prescribing atypical antipsychotics like Zyprexa off-label to treat behavioral disorders in elderly patients with dementia has been shown in clinical studies to be associated with nearly a two-fold increase in mortality, primarily due either to heart-related events, such as heart failure and sudden death, or to infections such as pneumonia."

The federal investigation into Lilly's Zyprexa marketing practices was conducted by the U.S. Attorney's Office for the Eastern District of Pennsylvania under the direction of acting U.S. Attorney Laurie Magid, Assistant U.S. Attorney Virginia Gibson, Chief of the Civil Division and Assistant U.S. Attorney Joe Trautwein.

Massachusetts Assistant Attorney General Bill Patten and Delaware Deputy Attorney General Dan Miller led the investigation on behalf of the states and the National Association of Medicaid Fraud Control Units ("NAMFCU").

UNITED STATES ex rel. STEVEN WOODWARD et al. v. ELI LILLY AND COMPANY, et al., Eastern District of Pennsylvania, CA No. 06-5526.

UNITED STATES ex rel. JAYDEEN VICENTE et al. v. ELI LILLY AND COMPANY, Eastern District of Pennsylvania, CA No. 07-1791.

Attn: Editors

Call Tavy Deming or Brian P. Kenney at 610-940-9099 to arrange availability for the complete news release; or other public material related to the case.

About Kenney, Egan, McCafferty & Young, P.C. (

A nationally known law firm, Kenney, Egan, McCafferty & Young, P.C. ("KEMY") was founded by former veteran federal prosecutors who now zealously advocate in the public interest for individuals, corporations, labor organizations, and employee benefit plan clients. The firm specializes in qui tam and tax whistleblower litigation and has recovered more than $2 billion for the government in False Claims Act and tax whistleblower cases.

    Brian P. Kenney, Esq.
    Tavy Deming, Esq.
    Kenney, Egan, McCafferty & Young, P.C.
    3031C Walton Road, Suite 202
    Plymouth Meeting, PA 19462

SOURCE Kenney, Egan, McCafferty & Young
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Whistleblowers Complaints Lead Eli Lilly to Pay $800 Million to Settle Civil Medicaid Fraud Charges, According to Berg & Androphy
2. Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa
3. Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
4. Lilly Files Form 8-K/A Detailing Pro Forma Impact of ImClone Acquisition
5. Lilly Sets Date and Conference Call for Fourth-Quarter and Full-Year 2008 Financial Results Announcement
6. Lilly Announces Dividend Increase
7. Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies
8. Lilly Global Day of Service Receives National and Local Recognition
9. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
10. Lilly Completes Acquisition of ImClone Systems
11. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
Post Your Comments:
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... The hospitals ... to several aspects of orthopedic care. They have received recognition for excellence from ... orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based on ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for ... with some of the staff members at their recovery center. The videos highlight some ... as some of the things that make their recovery program so unique. , “Making ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... award at Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, ... Chiropractor and University President Carl S. Cleveland III on October 16. , “Katie ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology: